GO:0034763 negative regulation of transmembrane transport: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034763 (negative regulation of transmembrane transport) is a biological process that reduces the rate, extent, or efficiency of transmembrane transport, which is the movement of ions, small molecules, or macromolecules across a membrane.
• Negative regulation can occur through direct inhibition of transporters or channels, reduction of their expression, altered membrane trafficking, or changes in driving forces such as electrochemical gradients.
• Key molecular players include CFTR, KCNQ1, TMC4, efflux pumps, and voltage-sensitive phosphatases, which modulate ion and solute flux across membranes.
• Dysregulation of negative regulation of transmembrane transport is linked to diseases such as cystic fibrosis, cancer chemoresistance, and cardiac arrhythmias.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise interrogation of genes that negatively regulate transmembrane transport.
• Studying this process requires integrated approaches including electrophysiology, live-cell imaging, proteomics, and CRISPR library screening.
Description
Transmembrane transport is the movement of ions, nutrients, and other solutes across biological membranes, a process essential for cellular homeostasis, signaling, and metabolism. The Gene Ontology term GO:0034763, negative regulation of transmembrane transport, describes any process that stops, prevents, or reduces the frequency, rate, or extent of transmembrane transport. This regulatory layer is critical because unchecked transport can lead to osmotic imbalance, excitotoxicity, or drug resistance. Understanding negative regulation of transmembrane transport is therefore fundamental to cell biology and medicine. For researchers, GO:0034763 provides a framework to study how cells fine-tune transport activity. Negative regulators include proteins that directly inhibit transporters, such as TMC4 acting on KCNQ1 potassium channels, or CFTR inhibitors that block chloride conductance. Other mechanisms involve efflux pump regulation in bacteria, copper transport oscillators in plants, and voltage-sensitive phosphatases that modulate plasma membrane potential. These examples highlight the diversity of negative regulatory strategies across organisms. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0034763, covering its definition, mechanisms, key genes, disease relevance, and experimental methods including CRISPR-based models.
negative regulation of transmembrane transport At A Glance
| GO ID | GO:0034763 |
|---|---|
| GO term | negative regulation of transmembrane transport |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Reduces or prevents the movement of ions and molecules across membranes |
| Regulatory mechanisms | Direct inhibition, expression changes, trafficking, gradient modulation |
| Example regulators | CFTR inhibitors, TMC4, efflux pump regulators, voltage-sensitive phosphatases |
| Disease relevance | Cystic fibrosis, cancer chemoresistance, cardiac arrhythmias, microbial resistance |
What Is GO:0034763?
GO:0034763, negative regulation of transmembrane transport, is a biological process that decreases the frequency, rate, or extent of transmembrane transport. Transmembrane transport itself is the directed movement of substances (such as ions, small molecules, or proteins) across a lipid bilayer, often mediated by transporters, channels, or pumps. Negative regulation can be achieved by inhibiting transporter activity, reducing transporter abundance, altering membrane localization, or changing the electrochemical gradients that drive transport. This term encompasses both direct molecular inhibition and indirect regulatory pathways.
Why Is negative regulation of transmembrane transport Important in Cell Biology?
Negative regulation of transmembrane transport is essential for maintaining cellular homeostasis and responding to environmental cues. Without proper negative regulation, excessive ion flux can cause excitotoxicity, osmotic stress, or cardiac dysfunction. In cancer, negative regulation of drug efflux pumps can overcome chemoresistance. In infectious diseases, understanding how bacteria negatively regulate efflux pumps informs antibiotic development. Thus, GO:0034763 is a nexus for therapeutic intervention and basic cell biology.
• Maintains ion homeostasis by preventing excessive transport activity.
• Modulates drug resistance by regulating efflux pump activity in bacteria and cancer cells.
• Controls airway surface liquid volume through CFTR regulation.
• Influences cardiac action potential via KCNQ1 channel inhibition.
• Regulates copper homeostasis in plants through a biochemical oscillator.
• Affects plasma membrane potential via voltage-sensitive phosphatases.
• Provides targets for treating cystic fibrosis, cancer, and arrhythmias.
• Enables precise control of nutrient and metabolite uptake.
• Plays a role in ferroptosis suppression and chemoresistance.
• Offers opportunities for CRISPR-based functional genomics.
What Happens During negative regulation of transmembrane transport?
Direct inhibition of transporters or channels
In simple terms: A protein blocks the opening or activity of a transporter, stopping ions from moving across the membrane.
Negative regulation often occurs through direct physical interaction between a regulatory protein and a transporter or channel. For example, TMC4 acts as a negative regulator of the KCNQ1 (Kv7.1) potassium channel, reducing potassium currents. Similarly, CFTR inhibitors bind to the channel and block chloride transport. This mode of regulation is rapid and reversible, allowing fine-tuning of transport activity.
Reduction of transporter expression or membrane trafficking
In simple terms: The cell makes fewer transporters or moves them away from the membrane, so less transport happens.
Transcriptional or post-transcriptional downregulation of transporter genes reduces the number of functional units at the membrane. For instance, TMEM160 inhibits KEAP1 to suppress ferroptosis and induce chemoresistance, indirectly affecting transport processes. Altered trafficking can also remove transporters from the plasma membrane, as seen in the regulation of copper transport in Arabidopsis.
Modulation of electrochemical gradients
In simple terms: Changing the electrical or chemical balance across the membrane makes transport less favorable.
Transporters rely on electrochemical gradients. Voltage-sensitive phosphatases, such as those requiring basigin association, can alter membrane potential and thereby negatively regulate transport. In plants, a biochemical oscillator regulates copper transport by modulating gradients. This indirect mechanism provides system-level control.
Regulation of efflux pump activity
In simple terms: Cells can turn down pumps that expel drugs or toxins, keeping more inside.
In bacteria like Pseudomonas aeruginosa, efflux pumps contribute to antimicrobial resistance. Negative regulation of these pumps can restore drug sensitivity. In cancer, inhibiting efflux pumps can overcome chemoresistance. Thus, negative regulation of transmembrane transport is a key determinant of drug efficacy.
Feedback and homeostatic control
In simple terms: When transport is too high, sensors trigger a response to bring it back down.
Cells employ feedback loops to maintain homeostasis. For example, ionocyte CFTR coordinates chloride absorption and secretion to balance airway fluid, involving negative regulatory components. Such feedback ensures that transport rates stay within physiological limits.
Key Genes Involved in GO:0034763 negative regulation of transmembrane transport
The following genes and proteins are experimentally validated participants in negative regulation of transmembrane transport, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CFTR | Chloride channel; its inhibitors negatively regulate transport | Cystic fibrosis, airway fluid balance |
| TMC4 | Negative regulator of KCNQ1 potassium channel | Cardiac arrhythmias, ion transport |
| KCNQ1 | Potassium channel; target of negative regulation | Long QT syndrome, cardiac function |
| TMEM160 | Inhibits KEAP1, suppresses ferroptosis, affects chemoresistance | Gastric cancer, ferroptosis |
| KEAP1 | Substrate of TMEM160; regulates oxidative stress response | Cancer chemoresistance |
| Efflux pumps (e.g., MexAB-OprM) | Export toxins and antibiotics; negatively regulated to reduce resistance | Pseudomonas aeruginosa infections |
| Voltage-sensitive phosphatase | Modulates membrane potential; requires basigin | Electrochemical coupling |
| Basigin | Chaperone for voltage-sensitive phosphatase | Plasma membrane regulation |
| Copper transporters (COPT, etc.) | Regulated by a biochemical oscillator | Plant copper homeostasis |
| Inner membrane translocases | Mediate protein transport; can be negatively regulated | Mitochondrial biogenesis |
| Ionocyte CFTR | Coordinates chloride absorption and secretion | Airway fluid balance |
| TMC4-KCNQ1 complex | Physical interaction reduces potassium current | Cardiac electrophysiology |
| CFTR potentiators/inhibitors | Small molecules that modulate CFTR activity | Drug discovery |
| KEAP1-NRF2 pathway | Regulates antioxidant response; linked to transport | Cancer therapy |
| Efflux pump regulators | Control expression of efflux genes | Antimicrobial resistance |
| Voltage-sensitive phosphatases | Dephosphorylate lipids to alter membrane potential | Cell signaling |
How Is negative regulation of transmembrane transport Regulated?
Negative regulation of transmembrane transport is itself regulated at multiple levels. Transcriptional control of transporter genes, post-translational modifications, and protein-protein interactions all influence the degree of inhibition. For example, TMC4 binding to KCNQ1 is a direct regulatory interaction. In bacteria, efflux pump expression is controlled by local repressors and global regulators. In plants, a biochemical oscillator involving copper transport proteins provides rhythmic regulation. Additionally, voltage-sensitive phosphatases are regulated by association with basigin, which is required for their electrochemical coupling function. These layers allow dynamic and context-specific control of transport activity.
negative regulation of transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CFTR | Cystic fibrosis, airway fluid imbalance | CFTR knockout or point-mutation cell lines |
| TMC4 | Cardiac arrhythmias | TMC4 overexpression or knockout in cardiomyocytes |
| TMEM160 | Gastric cancer chemoresistance | TMEM160 knockout or overexpression in gastric cancer cells |
| Efflux pumps | Antimicrobial resistance | Efflux pump knockout in Pseudomonas aeruginosa |
| KCNQ1 | Long QT syndrome | KCNQ1 knock-in mutations in iPSC-derived cardiomyocytes |
Cystic Fibrosis and Airway Disease
CFTR is a chloride channel whose dysfunction causes cystic fibrosis. Negative regulation of CFTR transport can be achieved by inhibitors, which are studied for therapeutic modulation. Ionocyte CFTR coordinates chloride absorption and secretion to balance airway fluid, and its dysregulation contributes to airway disease. Understanding negative regulation of CFTR is therefore critical for developing treatments.
Cancer Chemoresistance
TMEM160 inhibits KEAP1 to suppress ferroptosis and induce chemoresistance in gastric cancer. This illustrates how negative regulation of transmembrane transport (e.g., of iron or drugs) can promote tumor survival. Efflux pumps also contribute to chemoresistance by exporting drugs; their negative regulation could sensitize cancer cells.
Cardiac Arrhythmias
TMC4 acts as a negative regulator of KCNQ1 potassium channels, which are essential for cardiac action potential repolarization. Dysregulation of this interaction may lead to arrhythmias such as long QT syndrome. Thus, negative regulation of transmembrane transport is directly relevant to cardiac electrophysiology.
Antimicrobial Resistance
In Pseudomonas aeruginosa, efflux pumps contribute to antimicrobial resistance. Negative regulation of these pumps can reduce resistance and restore antibiotic efficacy. Therefore, targeting the regulatory pathways that control efflux pump activity is a promising strategy.
From negative regulation of transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate CFTR transport? | CFTR knockout or point-mutation cells with gene X overexpression |
| How does TMC4 inhibit KCNQ1? | TMC4 knockout and KCNQ1 knock-in in HEK293 or cardiomyocytes |
| Does TMEM160 regulate ferroptosis via KEAP1? | TMEM160 knockout gastric cancer cells |
| Can efflux pump regulation reverse resistance? | Efflux pump knockout in Pseudomonas aeruginosa |
| What is the role of voltage-sensitive phosphatase in transport? | Basigin knockout or phosphatase knock-in |
| How does copper transport oscillator work? | CRISPR knockout of copper transporters in Arabidopsis |
How to Study the negative regulation of transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp | Ion channel currents | CFTR, KCNQ1 regulation |
| Live-cell imaging | Ion flux, membrane potential | Airway fluid balance, phosphatase activity |
| Co-immunoprecipitation | Protein-protein interactions | TMC4-KCNQ1, TMEM160-KEAP1 |
| RNA-seq | Gene expression changes | Efflux pump regulation |
| CRISPR knockout screens | Gene function in transport regulation | Drug resistance, ion homeostasis |
| Proteomics | Protein abundance and modifications | Transporter regulation |
| Electrochemical assays | Gradient and potential changes | Voltage-sensitive phosphatase |
| Biochemical oscillator assays | Rhythmic transport activity | Copper homeostasis |
Electrophysiology
Patch-clamp and two-electrode voltage-clamp measure ion channel activity directly. These methods are used to quantify negative regulation of channels like CFTR and KCNQ1.
Live-Cell Imaging
Fluorescent dyes and genetically encoded sensors track ion flux and membrane potential in real time. This is useful for studying voltage-sensitive phosphatases and CFTR function.
Proteomics and Interactomics
Mass spectrometry identifies protein-protein interactions, such as TMC4-KCNQ1 or TMEM160-KEAP1, revealing negative regulatory complexes.
CRISPR Library Screening
Genome-wide knockout screens identify genes that negatively regulate transport, e.g., in drug resistance or ion homeostasis.
How CRISPR Can Be Used to Study GO:0034763 negative regulation of transmembrane transport
Knockout
CRISPR knockout of candidate negative regulators (e.g., TMC4, TMEM160) allows assessment of their role in transport. For example, TMEM160 knockout increases ferroptosis sensitivity. Knockout of efflux pumps reduces resistance.
Point Mutation
Introducing point mutations in transporters (e.g., CFTR, KCNQ1) mimics disease variants and tests regulation. CFTR point mutations are used to study channel function and drug response.
Knock-in
Knock-in of tagged or mutant versions of regulatory proteins enables tracking and functional analysis. For instance, knock-in of basigin mutants affects voltage-sensitive phosphatase localization.
Overexpression
Overexpression of negative regulators (e.g., TMC4) suppresses transport activity, confirming function. This approach is used to study KCNQ1 inhibition and CFTR regulation.
How EDITGENE Supports negative regulation of transmembrane transport Research
Researchers studying negative regulation of transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in transport regulation or is merely correlated. EDITGENE provides validated CRISPR models to establish causality and dissect molecular mechanisms.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of transmembrane transport research.
Frequently Asked Questions About negative regulation of transmembrane transport
What is GO:0034763?
GO:0034763 is the Gene Ontology term for negative regulation of transmembrane transport, a biological process that reduces the movement of substances across membranes.
What genes are involved in negative regulation of transmembrane transport?
Key genes include CFTR, TMC4, KCNQ1, TMEM160, KEAP1, efflux pumps, and voltage-sensitive phosphatases.
How does TMC4 regulate potassium transport?
TMC4 acts as a negative regulator of the KCNQ1 potassium channel, reducing potassium currents.
What is the role of CFTR in transmembrane transport?
CFTR is a chloride channel; its inhibitors negatively regulate chloride transport, and its function is critical for airway fluid balance.
How is negative regulation of transmembrane transport linked to cancer?
TMEM160 inhibits KEAP1 to suppress ferroptosis and induce chemoresistance, and efflux pumps contribute to drug resistance.
What experimental methods study negative regulation of transmembrane transport?
Patch-clamp, live-cell imaging, proteomics, and CRISPR screens are commonly used.
Can CRISPR be used to study negative regulation of transmembrane transport?
Yes, knockout, point mutation, knock-in, and overexpression models enable functional studies.
What diseases involve defective negative regulation of transmembrane transport?
Cystic fibrosis, cardiac arrhythmias, cancer chemoresistance, and antimicrobial resistance.
How do efflux pumps relate to GO:0034763?
Efflux pumps are transporters; their negative regulation reduces drug export and can reverse resistance.
What is the role of voltage-sensitive phosphatases in transport?
They modulate membrane potential and require basigin for electrochemical coupling, thereby affecting transport.
Conclusion
GO:0034763, negative regulation of transmembrane transport, is a fundamental biological process that controls ion and solute flux across membranes. Its dysregulation underlies diverse diseases, from cystic fibrosis to cancer chemoresistance. The genes and mechanisms highlighted here, supported by verified literature, provide a foundation for further research. CRISPR-based models from EDITGENE can accelerate the discovery of new regulatory pathways and therapeutic targets in this field.
References
- 1. Lorusso AB et al.. 2022. Role of Efflux Pumps on Antimicrobial Resistance in Pseudomonas aeruginosa.. Int J Mol Sci 23(24) PMID: 36555423
- 2. Huang C et al.. 2025. TMEM160 inhibits KEAP1 to suppress ferroptosis and induce chemoresistance in gastric cancer.. Cell Death Dis 16(1):287 PMID: 40223081
- 3. Liu F et al.. 2024. Structure-based discovery of CFTR potentiators and inhibitors.. Cell 187(14):3712-3725.e34 PMID: 38810646
- 4. De Geyter J et al.. 2019. Inner Membrane Translocases and Insertases.. Subcell Biochem 92:337-366 PMID: 31214992
- 5. Yuan F et al.. 2025. Ionocyte CFTR Coordinates Chloride Absorption and Secretion to Balance Airway Fluid.. Am J Respir Crit Care Med 211(10):1935-1950 PMID: 40815683
- 6. Aoyagi H et al.. 2026. Transmembrane channel-like 4 (TMC4) could act as a negative regulator of KCNQ1 (Kv7.1) potassium channel.. Biochim Biophys Acta Biomembr 1868(1):184460 PMID: 41046027
- 7. Peñarrubia L et al.. 2010. Regulation of copper transport in Arabidopsis thaliana: a biochemical oscillator?. J Biol Inorg Chem 15(1):29-36 PMID: 19798519
- 8. Shaikh IG et al.. 2025. Electrochemical coupling at the plasma membrane by mouse voltage-sensitive phosphatase requires association with basigin.. Cell Rep 44(9):116200 PMID: 40880230
